Advancing a Pipeline Designed to Support Lasting Progress in Obesity and Metabolic Health
Viking is developing next-generation therapies to manage obesity and metabolic disease. Our therapies are designed to help people achieve meaningful weight loss, maintain a healthy weight, and realize the associated long-term health benefits, including improved quality of life, physical function, and cardiovascular health.
| Program | Setting | Preclinical | Phase 1 | Phase 2 | Phase 3 | Status |
|---|---|---|---|---|---|---|
| Development Programs | ||||||
| VK2735 Subcutaneous (Dual GLP-1/GIP agonist) | Obesity | Phase 3 in process | ||||
| VK2735 Oral (Dual GLP-1/GIP agonist) | Obesity | Phase 3 planned 4Q26 | ||||
| VK2735 Sub-q & Oral (Dual GLP-1/GIP agonist) | Obesity-Maintenance | Phase 1 in process | ||||
| VK3019 (Amylin agonist) | Obesity | Phase 1 planned 2Q26 | ||||
| Additional Metabolic | ||||||
| VK2809 (TRβ Agonist) | MASH | Phase 2b VOYAGE trial successfully completed | ||||
| VK0214 (TRβ Agonist) | X-ALD | Phase 1b study demonstrated PoC | ||||
| VK5211 (prevention of lean mass (muscle) loss) |
SARM | |||||
| Development Programs | |||
| Preclinical | Phase 1 | Phase 2 | Phase 3 |
| VK2735 Subcutaneous (Dual GLP-1/GIP agonist) - Obesity | |||
| VK2735 Oral (Dual GLP-1/GIP agonist) - Obesity | |||
| VK2735 Sub-q & Oral (Dual GLP-1/GIP agonist) - Obesity-Maintenance | |||
| VK3019 (Amylin agonist) - Obesity | |||
| Additional Metabolic | |||
| Preclinical | Phase 1 | Phase 2 | Phase 3 |
| VK2809 (TRβ Agonist) - MASH | |||
| VK0214 (TRβ Agonist) - X-ALD | |||
| VK5211 (prevention of lean mass (muscle) loss) - SARM | |||
Next-Generation Obesity Therapies
VK2735
VK2735 is potentially the first dual GLP-1/GIP receptor agonist that will be available in both oral and injectable formulations. Currently in Phase 3 development for obesity, VK2735 has demonstrated a compelling efficacy and tolerability profile in clinical studies. The program has shown progressive weight loss over time without plateau, supporting the potential for sustained outcomes with longer-term use.
VK2735 has the potential to support patients throughout their weight-loss and health journey. It has been designed to offer treatment flexibility with the potential to switch between oral and subcutaneous formulations using the same active ingredient to support longer-term weight management.
Enrollment in the Phase 3 VANQUISH program has been completed, and the study is underway to assess the efficacy and safety of VK2735 administered subcutaneously once weekly for 78 weeks. This program includes two trials evaluating VK2735: one in adults with obesity (VANQUISH-1) and the other in adults with obesity and type 2 diabetes (VANQUISH-2). Viking is also evaluating maintenance dosing strategies for VK2735, focusing on long-term disease management and helping patients maintain progress and improve health beyond initial weight loss.
Expanding the Obesity Pipeline
VK3019
Viking is also advancing additional approaches in obesity treatment, including amylin-based therapies designed to expand treatment options and support durable outcomes and improvements in overall metabolic health.
These programs reflect Viking’s broader commitment to supporting long-term disease management and developing therapies designed for real-world use over time.
Metabolic and Liver Disease
VK2809
Building on our metabolic expertise, Viking is developing VK2809, an orally available small-molecule thyroid hormone receptor beta agonist, for the treatment of lipid and metabolic disorders.
In a Phase 2b study, VK2809 met both the primary and secondary endpoints for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis. It has also demonstrated significant reductions in LDL cholesterol and liver fat, supporting its potential to improve key drivers of metabolic disease and contribute to meaningful improvements in overall health.
Rare Disease
VK0214
Viking’s VK0214 is in development for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare and serious genetic disorder.
Clinical data have demonstrated VK0214 is well tolerated and reduces plasma levels of very long-chain fatty acids, supporting its potential to address the underlying biology of disease and improve patient outcomes over time.
